Polymeric nanoparticles have emerged as attractive carriers for cancer therapies and brain-related disorders due to their increased permeability and retention (EPR) effect. Cinnamic acid (CA), a multifunctional bioactive molecule with notable antioxidant, anti-inflammatory, and anticancer activities, was encapsulated into a polymeric nanoparticle system composed of polylactic acid and chitosan. Comprehensive physicochemical characterization demonstrated effective CA loading in polymeric nanoparticles by displaying a transition from crystalline-to-amorphous, which improved solubility and bioavailability. The CA loaded polylactic acid/chitosan nanoparticles (CA-PLA/CS NPs) were spherical and homogenous in size (80-135 nm) with a positive zeta potential of +8.17 mV that ensured colloidal stability. The sustained and pH-responsive drug release suited to tumor microenvironments and managing brain-related disorders. CA-PLA/CS NPs preserved substantial antioxidant activity and had anti-inflammatory effects equivalent to diclofenac sodium and hemolysis were below the acceptable safety threshold. Animal studies confirmed that retained neural, hepatic and renal morphology with no damage, indicating systemic tolerance. Pharmacokinetic tests demonstrated that CA-PLA/CS nanoparticles had higher plasma concentrations than free CA, demonstrating the delivery system's efficacy. Overall, CA-PLA/CS NPs formulation syndicates structural stability, biocompatibility, and therapeutic efficacy, creating a strong platform for targeted cancer medication delivery and brain-related disorders.
Mani et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: